The introduction of esketamine nasal spray represents a potential advancement in the treatment of complex depressive illness across the EU . While previously requiring hospital-based administration, this formulation allows for a more degree of recipient convenience , although rigorous monitoring remains vital . Preliminary results suggest benefit f